Unternehmensportrait
Viking Therapeutics, Inc. is a biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its lead candidate, VK2809, is in Phase IIb trials for non-alcoholic steatohepatitis. The company also focuses on treatments for diabetes and X-linked adrenoleukodystrophy.
Vorstand & Aufsichtsrat
Vorstandsvorsitzender |
Brian Lian |
Vorstand |
Greg Zante, Marianne Mancini, Geoffrey Barker, Michael Morneau |
Aufsichtsrat |
Lawson Macartney, Matthew W. Foehr, Kathy Rouan, Charles A. Rowland Jr., Matthew Singleton |
Unternehmensinformationen
Name: |
Viking Therapeutics Inc. |
Adresse: |
9920 Pacific Heights Blvd, Suite 350,San Diego, CA 92121 |
Telefon: |
+1-858-704-4660 |
Fax: |
- |
E-Mail: |
-
|
Internet: |
https://vikingtherapeutics.com/ |
Industrie: |
Biotechnologie |
Sektor: |
Biotechnologie |
Sub-Sektor: |
Biotechnologie |
Ende des Finanzjahres: |
31.12 |
Streubesitz: |
92,05% |
IPO Datum: |
- |